Anticancer molecule AS1411 exhibits low nanomolar antiviral activity against HIV-1.
Language
EN
Article de revue
This item was published in
Biochimie. 2015-11-01, vol. 118, p. 173-5
English Abstract
During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for ...Read more >
During clinical trials, a number of fully characterized molecules are dropped along the way because they do not provide enough benefit for the patient. Some of them show limited side effects and might be of great use for other applications. AS1411 is a nucleolin-targeting aptamer that underwent phase II clinical trials as anticancer agent. Here, we show that AS1411 exhibits extremely potent antiviral activity and is therefore an attractive new lead as anti-HIV agent.Read less <
English Keywords
Anti-HIV Agents
Antineoplastic Agents
Aptamers
Nucleotide
Cell Line
Cell Proliferation
HIV-1
Humans
Oligodeoxyribonucleotides